Kringle Pharma, Inc. 4884

TSE · Japan · Health Technology

¥484.00-13.00 (-2.62%)

Market closed· Oct 2, 2026, 6:30 AM UTC· JPY · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Kringle Pharma, Inc. 4884

TSE · Japan · Health Technology

¥484.00-13.00 (-2.62%)

Market closed· Oct 2, 2026, 6:30 AM UTC· JPY · Data may be delayed

Company news

Yahoo FinanceApr 02, 2026

The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight

The SCI treatment pipeline continues to expand, featuring candidates such as KP-100IT (Kringle Pharma), Neuro-Cells (Neuroplast), MT-3921 (Mitsubishi Tanabe Pharma America), Elezanumab (AbbVie), PMZ-1620 (Pharmazz), NFX88 (Neurofix), NVG-291 (NervGen Pharma), and others. The introduction of these innovative spinal cord injury therapies is expected to revolutionize the SCI treatment landscape in the coming years.New York, USA, April 02, 2026 (GLOBE NEWSWIRE) -- The Rise of 6 Emerging Therapies in

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.